Neutrophil extracellular traps in relationship to efficacy of systemic therapy for metastatic renal cell carcinoma

Abstract

AbstractBackgroundThe efficacy of systemic therapy regimens, such as immune checkpoint inhibitors and tyrosine kinase inhibitors (IO‐TKI) and targeted therapy, for metastatic clear cell renal cell carcinoma (ccRCC) remains unpredictable due to the lack of effective biomarkers. Neutrophil extracellular trap (NET) plays an important role in promoting ccRCC. This study explores the NET predictive value of the efficacy in metastatic ccRCC.MethodsIn this retrospective study, patients with metastatic ccRCC who received targeted drugs and IO‐TKI were included. Immunofluorescence staining was utilized to quantify the levels of tissue NETs through cell counts of H3Cit(+) and MPO(+) cells.ResultsA total of 183 patients with metastatic ccRCC were enrolled, including 150 patients who received TKIs and 33 patients who received IO‐TKI. The levels of NETs in tumor tissue were significantly higher than in para‐tumor tissue (p < 0.001). In terms of predicting drug efficacy, a correlation between NET levels and progression‐free survival (PFS) was observed in the TKI with metachronous metastasis group (HR 1.73 [95% CI 1.02–2.91], log‐rank p = 0.037), while no correlation was observed in the TKI with synchronous metastasis group and IO‐TKI group. Regarding overall survival (OS), activated NET levels were associated with poor OS in both TKI (HR 1.60 [95% CI 1.05–2.43], log‐rank p  = 0.017) and IO‐TKI group (HR 4.35 [95% CI 1.06–17.82], log‐rank p =0.047). IMDC score (HR 1.462 [95% CI 1.030–2.075], p = 0.033) and tumor tissue NET levels (HR 1.733 [95% CI 1.165–2.579], p = 0.007) were independent prognostic risk factors for OS in patients with metastatic ccRCC.NET level was associated with poor OS in both TKI (HR 1.60 [95% CI 1.05–2.43], log‐rank p  = 0.017).ConclusionsThe active NET levels in tumor tissue can predict drug efficacy in patients with metastatic ccRCC who received systemic therapy. Elevated levels of NETs in tumor tissue were also associated with poor efficacy in OS.